Compare RAYA & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAYA | SCNX |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Other Pharmaceuticals |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 24.8M |
| IPO Year | 2022 | 2020 |
| Metric | RAYA | SCNX |
|---|---|---|
| Price | $4.63 | $0.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.1K | ★ 1.8M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,101,325.00 | $653,391.00 |
| Revenue This Year | $20.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 18.78 | ★ 207.88 |
| 52 Week Low | $3.13 | $0.46 |
| 52 Week High | $736.99 | $8.19 |
| Indicator | RAYA | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 45.74 |
| Support Level | $3.70 | $0.60 |
| Resistance Level | $5.62 | $0.75 |
| Average True Range (ATR) | 0.50 | 0.06 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 56.96 | 34.54 |
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.